Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells

Copyright © 2014 Elsevier Inc. All rights reserved.

Bibliographische Detailangaben
Veröffentlicht in:Clinical immunology (Orlando, Fla.). - 1999. - 155(2014), 2 vom: 04. Dez., Seite 160-75
1. Verfasser: Wang, Yao (VerfasserIn)
Weitere Verfasser: Zhang, Wen-ying, Han, Qing-wang, Liu, Yang, Dai, Han-ren, Guo, Ye-lei, Bo, Jian, Fan, Hui, Zhang, Yan, Zhang, Ya-jing, Chen, Mei-xia, Feng, Kai-chao, Wang, Quan-shun, Fu, Xiao-bing, Han, Wei-dong
Format: Online-Aufsatz
Sprache:English
Veröffentlicht: 2014
Zugriff auf das übergeordnete Werk:Clinical immunology (Orlando, Fla.)
Schlagworte:Journal Article Research Support, Non-U.S. Gov't Anti-CD20 chimeric antigen receptor (CAR) T cells; Delayed toxicities Diffuse large B-cell lymphoma (DLBCL); Refractory advanced; Antigens, CD20 Receptors, Antigen, T-Cell Recombinant Fusion Proteins Tumor Necrosis Factor Receptor Superfamily, Member 9
LEADER 01000caa a22002652 4500
001 NLM24399365X
003 DE-627
005 20250217194423.0
007 cr uuu---uuuuu
008 231224s2014 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.clim.2014.10.002  |2 doi 
028 5 2 |a pubmed25n0813.xml 
035 |a (DE-627)NLM24399365X 
035 |a (NLM)25444722 
035 |a (PII)S1521-6616(14)00238-1 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Wang, Yao  |e verfasserin  |4 aut 
245 1 0 |a Effective response and delayed toxicities of refractory advanced diffuse large B-cell lymphoma treated by CD20-directed chimeric antigen receptor-modified T cells 
264 1 |c 2014 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 19.02.2015 
500 |a Date Revised 08.01.2021 
500 |a published: Print-Electronic 
500 |a ClinicalTrials.gov: NCT01735604 
500 |a Citation Status MEDLINE 
520 |a Copyright © 2014 Elsevier Inc. All rights reserved. 
520 |a We conducted a trial testing a CD20-specific CAR coupled with CD137 and the CD3ζ moiety in patients with chemotherapy refractory advanced diffuse large B cell lymphomas (DLBCL). Seven patients were enrolled. One of the two patients with no bulky tumor obtained a 14-month durable and ongoing complete remission by cell infusion only, and another attained a 6-month tumor regression. Four of five patients with bulky tumor burden were evaluable for clinical efficacy, three of which attained 3- to 6-month tumor regression. Delayed toxicities related to cell infusion are directly correlated to tumor burden and tumor-harboring sites, and mainly included cytokine release symptoms, tumor lysis symptoms, massive hemorrhage of the alimentary tract and aggressive intrapulmonary inflammation surrounding extranodal lesions. These results show firstly that anti-CD20 CART cells can cause prolonged tumor regression in combination with debulking conditioning regimens for advanced DLBCL. This study is registered at www.clinicaltrials.gov as NCT01735604 
650 4 |a Journal Article 
650 4 |a Research Support, Non-U.S. Gov't 
650 4 |a Anti-CD20 chimeric antigen receptor (CAR) T cells; 
650 4 |a Delayed toxicities 
650 4 |a Diffuse large B-cell lymphoma (DLBCL); 
650 4 |a Refractory advanced; 
650 7 |a Antigens, CD20  |2 NLM 
650 7 |a Receptors, Antigen, T-Cell  |2 NLM 
650 7 |a Recombinant Fusion Proteins  |2 NLM 
650 7 |a Tumor Necrosis Factor Receptor Superfamily, Member 9  |2 NLM 
700 1 |a Zhang, Wen-ying  |e verfasserin  |4 aut 
700 1 |a Han, Qing-wang  |e verfasserin  |4 aut 
700 1 |a Liu, Yang  |e verfasserin  |4 aut 
700 1 |a Dai, Han-ren  |e verfasserin  |4 aut 
700 1 |a Guo, Ye-lei  |e verfasserin  |4 aut 
700 1 |a Bo, Jian  |e verfasserin  |4 aut 
700 1 |a Fan, Hui  |e verfasserin  |4 aut 
700 1 |a Zhang, Yan  |e verfasserin  |4 aut 
700 1 |a Zhang, Ya-jing  |e verfasserin  |4 aut 
700 1 |a Chen, Mei-xia  |e verfasserin  |4 aut 
700 1 |a Feng, Kai-chao  |e verfasserin  |4 aut 
700 1 |a Wang, Quan-shun  |e verfasserin  |4 aut 
700 1 |a Fu, Xiao-bing  |e verfasserin  |4 aut 
700 1 |a Han, Wei-dong  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Clinical immunology (Orlando, Fla.)  |d 1999  |g 155(2014), 2 vom: 04. Dez., Seite 160-75  |w (DE-627)NLM098196855  |x 1521-7035  |7 nnns 
773 1 8 |g volume:155  |g year:2014  |g number:2  |g day:04  |g month:12  |g pages:160-75 
856 4 0 |u http://dx.doi.org/10.1016/j.clim.2014.10.002  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_24 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 155  |j 2014  |e 2  |b 04  |c 12  |h 160-75